Aspects of pulmonary infections after solid organ transplantation

Current Infectious Disease Reports

Volumn 2, Issue 3, 2000, Pages 201-206

  Catalla, Robert ^a   Leaf, Howard L ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aspergillosis; Invasive Aspergillosis; Itraconazole; Orthotopic Liver Transplantation; Transplant Recipient

Indexed keywords

EID: 0012410057     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-000-0036-6     Document Type: Article

References (49)

1. Ettinger NA, Trulock EP: Pulmonary considerations of organ transplantation. Am Rev Respir Dis 1991, 143:1386–1405.
2. Gorensek MJ, Stewart RW, Keyus TF, et al.: A multivariate analysis of risk factors for pneumonia following cardiac transplantation. Transplantation 1988, 48:860–865.
3. Austin JHM, Schulman LL, Mastrobattista JD: Pulmonary infection after cardiac transplantation: clinical and radiologic correlations. Radiology 1989, 172:259–265.
4. Nunley D, Dauber J: Lung transplantation: implications for the general internist. Adv Intern Med 1996, 41:497–529.
5. Weisner R: The incidence of gram-negative bacterial and fungal infections in liver transplant patients treated with selective decontamination. Infection 1990, 18(suppl 1):S19-S21.
6. Singh N, Gayowski T, Wagener M, Marino I: Pulmonary infiltrates in liver transplant recipients in the intensive care unit. Transplantation 1999, 67:1138–1144.
7. Ettinger N, Bailey TC, Trulock EP, et al.: Cytomegalovirus infection and pneumonitis. Impact after isolated lung transplantation. Washington University Lung Transplant Group. Am Rev Respir Dis 1993, 147:1017–1023.
8. Fishman JA, Rubin RH: Infection in organ transplant recipients. N Engl J Med 1998, 338:1741–1751.
9. Ettinger N, Trulock E: Pulmonary considerations after organ transplantation. Rev Respir Dis 1991, 143:1386–1405.
10. Merigan TC, Renlund DG, Keay S, et al.: A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med 1992, 326:1182–1186.
11. Snydman DR: Prevention of cytomegalovirus associated diseases with immunoglobulin. Transplant Proc 1991 23(suppl 1):131–135.
12. Conti DJ, Freed BM, Gruber SA, et al.: Prophylaxis of primary cytomegalovirus disease in renal transplant recipients. A trial of ganciclovir vs. immunoglobulin. Arch Surg 1994, 129:443–447.
13. Zamora MR, Fullerton DA, Campbell DN, et al.: Use of cytomegalovirus hyperimmune globulin for prevention of CMV disease in CMV seropositive lung transplant recipients. Transplant Proc 1994, 26 (suppl 1):49–51.
14. Gane E, Saliba F, Valdecasas G, et al.: Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant patients. Lancet 1997, 350:1729–1733.
15. Hibberd P, Tolkoff-Rubin N, Conti D, et al.: Preemptive therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant patients: a randomized controlled trial. Ann Intern Med 1995, 123:18–26.
16. Lowance D, Neumayer H, Legendre C, et al.: Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med 1999, 340:1462–1470. A randomized trial of valacyclovir versus placebo as CMV prophylaxis in 616 at-risk renal transplant recipients. Valacyclovir was shown to be safe and effective.
17. Starnes VA, Theodore J, Oyer PE, et al.: Evaluation of heartlung transplant recipients with prospective, serial transbronchial biopsies and pulmonary function studies. J Thorac Cardiovasc Surg 1989, 98:683–690.
18. Higenbottam T, Stewart S, Penketh A, Wallwork J: Transbronchial biopsy for the diagnosis of rejection in heart-lung transplant patients. Transplantation 1988, 46:532–539.
19. Ettinger N, Bailey TC, Trulock EP, et al.: Cytomegalovirus infection and pneumonitis: impact after isolated lung transplantation. Am Rev Respir Dis 1993, 147:1017–1023.
20. Aafedt BC, Halvorsen RA, Tylen U, Hertz M: Cytomegalovirus pneumonia: computed tomography findings. J Can Assoc Radiol 1990, 41:276–280.
21. McGuiness G, Scholes JV, Garay SM, et al.: Cytomegalovirus pneumonitis: spectrum of parenchymal CT findings with pathologic correlation in 21 AIDS patients. Radiology 1994, 192:451–459.
22. Gerna G, Furione M, Baldanti F, et al.: Comparative quantitation of human cytomegalovirus DNA in blood leukocytes and plasma of transplant and AIDS patients. J Clin Microbiol 1994, 32:2709–2717.
23. Cagle P, Buffone G, Holland VA, et al.: Semiquantitative measurement of cytomegalovirus DNA in lung and heartlung transplant patients by in vitro DNA amplification. Chest 1992, 101:93–96.
24. Boeckh M, Boivin G: Quantitation of cytomegalovirus: methodologic aspects and clinical applications. Clin Microbiol Rev 1998, 11(3):533–554. Various techniques, such as culturing, antigen detection, and DNA detection assays, are discussed in the context of early detection and monitoring of the response to therapy.
25. Sturba A, Viale D, Podesta O, et al.: CMV pp67 mRNA amplification performance in the diagnosis of CMV active infections in immunocompromised patients [abstract 1953]. San Francisco: Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999:439.
26. Limaye A, Corey L, Koelle D, et al.: Emergence of ganciclovirresistant cytomegalovirus disease among solid organ transplant recipients [abstract LB-1]. San Francisco: Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999:13.
27. Fishman JA: Pneumocystis carinii and parasitic infection in transplantation. Infect Dis Clin North Am 1995, 9:1005–1044.
28. Rubin RH: Infection in organ transplant recipients. In Clinical Approach to Infection in the Immunocompromised Host, edn 3. Edited by Rubin R, Young L. New York: Plenum Medical Book Company; 1994.
29. Olsen SL, Renlund DG, O’Connell JB, et al.: Prevention of Pneumocystis carinii pneumonia in cardiac transplant recipients by trimethoprim sulfamethoxazole. Transplantation 1993, 56:359–362. A thorough review from members of the Massachusetts General Hospital transplant group.
30. Gordon S, LaRosa S, Kalmadi S, et al.: Should prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients ever be discontinued? Clin Infect Dis 1999, 28:240–246. The Cleveland Clinic experience with PCP in SOT from 1987 to 1996 is reviewed. The authors conclude that a duration of prophylaxis beyond 1 year for lung transplant patients may be warranted.
31. Collin B, Ramphal R: Pneumonia in the compromised host including cancer patients and transplant patients. Infect Dis Clin North Am 1998, 12(3):781–805.
32. Singh N, Paterson D: Mycobacterium tuberculosis infection in solid organ transplant recipients: impact and implications for management. Clin Infect Dis 1998, 27:1266–1277. A compilation of published reports in the literature.
33. Jereb J, Burwen D, Dooley S, et al.: Nosocomial outbreak of tuberculosis in a renal transplant unit: application of a new technique for restriction fragment length polymorphism analysis of mycobacterium tuberculosis isolates. J Infect Dis 1993, 168:1219–1224.
34. Kramer M, Denning D, Marshall S, et al.: Ulcerative tracheobronchitis after lung transplantation. Am Rev Respir Dis 1991, 144:552–556.
35. Hay RJ: The prevention of invasive aspergillosis—a realistic goal? J Antimicrob Chemother 1993, 32:515–517.
36. Paterson DL, Singh N: Invasive aspergillosis in transplant patients. Medicine 1999, 78:123–138. A review of the literature and the Pittsburgh experience.
37. Freeberg G, Levine S, White DS, et al.: Spectrum of pulmonary aspergillosis in immunocompromised hosts. Chest 1990, 98:31S.
38. de Repentigny L: Serodiagnosis of candidiasis, aspergillosis and cryptococcosis. Clin Infect Dis 1992, 12(suppl 1):S11-S22.
39. Kurup V, Kumar A: Immunodiagnosis of aspergillosis. Clin Microbiol Rev 1991, 4:439–456.
40. Patterson T, Miniter P, Patterson J, et al.: Aspergillus antigen detection in the diagnosis of invasive aspergillosis. J Infect Dis 1995, 171:1553–1558.
41. Fortun J, Munoz P, Montejo M, et al.: Efficacy and safety of Ambisome and Abelcet in transplant patients: a multicenter study [abstract 1644]. San Francisco: Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999:574.
42. Wimberly S, Haug M, Shermock K, et al.: Enhanced cyclosporine-itraconazole with cola in lung transplant recipients [abstract 13]. San Francisco: Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999:4.
43. Colby W, Sharpe M, Ghent C, et al.: Efficacy of itraconazole prophylaxis against systemic fungal infection in liver transplant recipients [abstract 1650]. San Francisco: Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999:576.
44. Munoz P, Palomo J, Yanez J, et al.: Primary prophylaxis with itraconazole of invasive aspergillosis in heart transplant patients [abstract 1416]. San Francisco: Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999:566.
45. Chaparro S, Celis D, Montoya J: Natural history of invasive pulmonary aspergillosis in heart transplant patients. San Francisco: Abstracts of the 1999 Infectious Disease Society of America Conference; 1999.
46. Gavalda J, Roman A, Bravo C, et al.: Pharmacokinetics and distribution of nebulized amphotericin B in lung transplantation [abstract 1925]. San Francisco:Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999:47.
47. Jones J, Allen R, Vu T, Cohen S: Use of voriconazole to treat invasive fungal infections in solid organ and bone marrow transplant recipients. San Francisco: Abstracts of the 1999 Infectious Disease Society of America; 1999.
48. Moore C, Walls C, Denning D: In vitro activity of the new triazole BMS-207147 against Aspergillus species and comparison with itraconazole or amphotericin B [abstract 1514]. San Francisco: Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999:9.
49. Najvar L, Bocanegra R, Sanche S, Graybill J: Efficacy of LY 303366 in mice with itraconazole resistant aspergillosis. Abstract 2002. San Francisco: Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy 1999:581.